- Home
- OM vs PACB Comparison
OM vs PACB Comparison
Compare OM & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- PACB
- Stock Information
- Founded
- OM 2003
- PACB 2000
- Country
- OM United States
- PACB United States
- Employees
- OM N/A
- PACB N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- OM Health Care
- PACB Industrials
- Exchange
- OM Nasdaq
- PACB Nasdaq
- Market Cap
- OM 305.5M
- PACB 364.2M
- IPO Year
- OM 2020
- PACB 2010
- Fundamental
- Price
- OM $18.53
- PACB $1.54
- Analyst Decision
- OM Buy
- PACB Buy
- Analyst Count
- OM 2
- PACB 9
- Target Price
- OM $33.00
- PACB $2.06
- AVG Volume (30 Days)
- OM 411.2K
- PACB 8.9M
- Earning Date
- OM 08-06-2025
- PACB 08-07-2025
- Dividend Yield
- OM N/A
- PACB N/A
- EPS Growth
- OM N/A
- PACB N/A
- EPS
- OM N/A
- PACB N/A
- Revenue
- OM $115,273,000.00
- PACB $152,357,000.00
- Revenue This Year
- OM $10.80
- PACB $3.33
- Revenue Next Year
- OM $11.99
- PACB $17.88
- P/E Ratio
- OM N/A
- PACB N/A
- Revenue Growth
- OM N/A
- PACB N/A
- 52 Week Low
- OM $5.85
- PACB $0.85
- 52 Week High
- OM $59.33
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- OM 48.27
- PACB 57.34
- Support Level
- OM $17.16
- PACB $1.35
- Resistance Level
- OM $19.60
- PACB $1.76
- Average True Range (ATR)
- OM 1.17
- PACB 0.11
- MACD
- OM -0.16
- PACB 0.00
- Stochastic Oscillator
- OM 35.06
- PACB 46.34
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.